BIIB News Alert Biogen Idec Inc (BIIB) 341.18 12/04/2014 17:

New Post Public Reply Private Reply Replies (0) Message Board

Dec 4, 2014 at 6:00 PM

Biogen Idec Inc (BIIB) 341.18 $BIIB

Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - 1 hr 13 mins ago
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 341.18 (-6.16), ARE: 88.12 (+1.73), GILD: 101.82 (+0.94), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03)

Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - 2 hrs 46 mins ago

AGN: 213.71 (+1.74), BIIB: 341.18 (-6.16), GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), NVS: 95.77 (+0.11)

Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 50 mins ago
Synageva BioPharma Corp. (GEVA) announced the completion of the rolling submission of a biologics license application to the FDA for sebelipase alfa for LAL deficiency.
CYTK: 4.56 (-0.07), BIIB: 341.18 (-6.16), GEVA: 81.77 (+0.43), AMGN: 166.55 (-1.52)

Array BioPharma Regains Binimetinib Rights from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:00PM CST
Shares of Array BioPharma Inc. (ARRY) shot up in after-market hours trading after the company announced reaching a definitive agreement with Novartis (NVS) to regain full worldwide rights to oncology candidate binimetinib, an MEK inhibitor.
BIIB: 341.18 (-6.16), GSK: 45.89 (-0.82), ARRY: 4.47 (+0.56), NVS: 95.77 (+0.11)

Will New Alzheimer's Drug Boost Biogen?
at Investor's Business Daily - Thu Dec 04, 11:32AM CST
Today we'll check in on Biogen Idec (BIIB), which develops treatments for multiple sclerosis, cancer and autoimmune diseases. It's also been working on a drug to slow Alzheimer's, called BIIB-037. Earlier this week, Biogen said it's moving that drug...
BIIB: 341.18 (-6.16)

Stock Market Today: Stocks Worsen Near Midday; Airlines Rally
at Investor's Business Daily - Thu Dec 04, 10:52AM CST
Stocks took a turn for the worse near Thursday's midday, as the Nasdaq erased gains. The S&P 500 and the Dow Jones industrial average lost 0.5% each. Both wiped out all of Wednesday's gains and then some. The Nasdaq fell 0.3% after giving up a 0.2%...
BIIB: 341.18 (-6.16), RYAAY: 68.08 (+4.55), ALK: 56.74 (-0.02), BITA: 78.21 (-1.20), UAL: 61.75 (+2.46)

The Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen
PR Newswire - Thu Dec 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).
BIIB: 341.18 (-6.16), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25)

Can the Rally in Biogen (BIIB) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:06AM CST
Can the Rally in Biogen (BIIB) Shares Continue?
BIIB: 341.18 (-6.16)

ADMA Biologics Slumps: ADMA Tanks 11% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:53AM CST
ADMA Biologics has been witnessing a positive trend in its current year estimate revision and its share price has been falling for past few days
BIIB: 341.18 (-6.16), ADMA: 10.80 (+0.19), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)

Prothena Corporation (PRTA) Falls: Stock Goes Down 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:37AM CST
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down over 9% since Nov 28. Although this slump was obviously disappointing the company has seen positive revisions and its current year loss consensus has narrowed over the past few weeks.
BIIB: 341.18 (-6.16), ANIP: 53.45 (-6.76), PRTA: 21.44 (-0.55), AFFX: 9.14 (-0.04)

Why Isis Pharmaceuticals, Inc. Stock Leaped 12% in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 7:32AM CST
ISIS data by YCharts What: Shares of Isis Pharmaceuticals , a biopharmaceutical company focused on using its proprietary antisense technology platform to develop therapies across a wide range of disease implications, motored ahead by 12% in...
BIIB: 341.18 (-6.16), ISIS: 52.68 (-0.93), AZN: 73.94 (+0.12)

Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 6:21AM CST
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rise by nearly 24% on the day.
BIIB: 341.18 (-6.16), SQNM: 3.67 (-0.10), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)

Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 04, 5:04AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 3. CEO interview: Manny Chirico, PVH (NYSE: PVH ). Other stock mentioned: J.C. Penney (NYSE: JCP ) PVH ( PVH ) delivered an 8 cent earnings...
BIIB: 341.18 (-6.16), HON: 99.26 (-0.71), UTX: 111.21 (+0.22), KMB: 114.60 (-0.10), INTC: 37.46 (+0.03), PVH: 122.68 (-1.72), SLB: 87.43 (+0.67), PEP: 97.75 (-0.57), GWPH: 74.55 (-1.46), EOG: 93.00 (+1.20), REGN: 423.21 (-1.20), CSCO: 27.77 (-0.18), MU: 36.07 (-0.03), SWKS: 69.75 (+3.08), HAL: 40.74 (-0.01), SN: 9.06 (-0.88), BMY: 58.89 (-0.14), BA: 131.32 (-0.65), HPQ: 39.07 (+0.02), CELG: 113.63 (-0.60), ZTS: 44.00 (-0.88), GILD: 101.82 (+0.94), TXN: 55.41 (-0.21), JCP: 6.73 (-0.46), PG: 90.58 (+0.58), PAY: 35.96 (+0.15), SWHC: 9.41 (-0.10)

Puma Biotechnology Down on Delay in Neratinib NDA Filing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 4:10PM CST
Shares of Puma Biotechnology, Inc. (PBYI) plunged significantly in after-market hours trading following the company's announcement that the NDA on pipeline candidate neratinib (PB272) will be delayed till the first quarter of 2016.
BIIB: 341.18 (-6.16), PFE: 31.67 (-0.08), PBYI: 195.55 (-2.12)

Stock Market Today: Indexes Close Near Day's Highs
at Investor's Business Daily - Wed Dec 03, 3:25PM CST
The stock market rose Wednesday, closing near session highs for a second straight day. The Nasdaq and S&P 500 climbed 0.4% and the Dow Jones industrial average 0.2%. The Russell 2000 outperformed, rising 1.1%. Volume fell across the board, according...
BIIB: 341.18 (-6.16), GIL: 52.95 (-5.32), GIII: 96.10 (-0.68), ADI: 56.62 (+0.11)

Biogen: Big Biotech Play Ready To Move
Bret Jensen - at Seeking Alpha - Wed Dec 03, 2:30PM CST

BIIB: 341.18 (-6.16)

Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 341.18 (-6.16), UTHR: 129.05 (-3.30)

Biogen Up on Encouraging Interim Data on Alzheimer's Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 1:33PM CST
Biogen (BIIB) reported encouraging interim results from an early-stage study on its anti-amyloid beta antibody, BIIB037, for the treatment of Alzheimer.
BIIB: 341.18 (-6.16), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25)

Myriad Genetics' Prolaris: A Pocket-Friendly Cancer Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 1:00PM CST
Myriad Genetics' (MYGN) Prolaris is the first prognostic test that allows a healthcare provider to directly measure the molecular biology of an individual patient's prostate cancer.
BIIB: 341.18 (-6.16), MYGN: 34.68 (+0.13), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)

Jim Cramer on the Stock Market: You Have to Love Biotech
at The Street - Wed Dec 03, 11:29AM CST
In this era of turmoil, investors can take comfort in this sector.
BIIB: 341.18 (-6.16), AVNR: 16.96 (+0.04), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03), REGN: 423.21 (-1.20), NVS: 95.77 (+0.11), CELG: 113.63 (-0.60)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CNOOC Limited's 2026 Surge: New Projects, New Heights

Production Peaks and New Discoveries Over in the bustling corridors of oil and gas, CNOOC Limited is making some strong waves. Why? Because they’ve hit historical peaks in production in the first three quarters of 2026. We’re talking about a net production of 593.7 million barrels of oil equivalent. That’s a 2.7% climb from last year. Seems like CNOOC is really...

Junior Golf Stars Shine at Notah Begay III Championship

Ever wonder where the golf stars of tomorrow get their start? Well, you might find a few of 'em teeing off at the Notah Begay III Junior Golf National Championship. This year, the spotlight is shining on the fairways of the Coushatta Resort in Louisiana. And let me tell you, the talent pool is something to behold. Young golfers from across the globe are swinging their way...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

City National Grows with New Inglewood Branch

By Riley Hayes Updated Oct 29, 2026 Category News Views 134

Inglewood, the New Banking Frontier It's not every day you see a bank banking on Inglewood, so to speak. Yet here we are. City National Bank is setting up shop in this buzzing part of Los Angeles, and it's high time someone paid attention to this vibrant hub. With major players in sports, entertainment, healthcare, and even aerospace calling Inglewood home, there's plenty...

Alfa Laval Secures EUR 1B Credit Facility Extension

Alfa Laval Banks on a New Financial Horizon Forget your morning rituals, Alfa Laval just pulled off a maneuver that's got industry tongues wagging. Thanks to a new EUR 1 billion revolving credit facility, they've bolstered their financial defenses, setting a robust foundation for the future. The facility, no dink-and-dunk affair, carries an initial five-year maturity. And...

Florida's Natural, Johnsonville Settle Bet Over Juice

No Such Thing as a Safe Bet When Milwaukee's Brewers edge out Tampa, it's not just about the wins and losses—it's about pride and a truckload of Florida's Natural orange juice cruising into Wisconsin. Who knew baseball could drive trades not just between players, but entire industries? In this friendly wager, the stakes were both flavorful and steep, paying homage to...

Rockford Fosgate Elevates Marketing Maverick to Lead Role

Changing the Guard in High-Performance Audio Marketing Out of Arizona, we get a shake-up that feels like a no-brainer for anyone in the high-performance audio market. Rockford Fosgate decided to elevate Tammy Lowe to the Vice President of Marketing role, effective immediately. With nearly four decades under her belt at the sunny Tempe-based HQ, it's hard to argue with the...

AeroSafe Tackles Cold-Chain Waste, Hosts Symposium

Sustainability in Healthcare Logistics: A Closer Look Ah, waste management in healthcare—a topic that doesn't quite light up the room, but here's the kicker: it's more important now than ever. With sustainability now a hard-hitting issue staring biopharma right in the face, AeroSafe Global's upcoming virtual Sustainability Symposium on November 10 is making some noise....

HIZENERGY Rolls Out Power-Packed BESS for Europe

Powering Europe's Energy Shift with HIZENERGY Ever felt like you're lost in the frenzy of Europe's energy transition? Well, HIZENERGY is diving headfirst into the chaos with their spiffy Commercial & Industrial Battery Energy Storage Systems (C&I BESS). Amid Europe's hunt for grid stability—with whiplash-inducing solar adoption and electricity pricing that behaves like...

Duolingo Faces Legal Storm: Investors Called to Act

Stirring the Pot at Duolingo You know what's worse than learning a new language? Finding out the company teaching it might have pulled a few fast ones on the market. That's right, folks, buckle up because Duolingo (NASDAQ: DUOL) is in hot water with a class action lawsuit hanging over its head, like a cloud of bad grammar questions. What's Up with the Lawsuit? This isn't...